Market Closed

CLYM
Climb Bio
$ 10.36
-4.69%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago

Climb Bio News

Latest Climb Bio Stock News & CLYM Headlines

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
11 days ago | globenewswire.com
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
12 days ago | globenewswire.com
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
14 days ago | globenewswire.com
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
22 days ago | globenewswire.com
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
23 days ago | globenewswire.com
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
a month ago | zacks.com
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
a month ago | seekingalpha.com
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
a month ago | globenewswire.com
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
2 months ago | marketbeat.com
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
2 months ago | benzinga.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

CLYM
Climb Bio
$ 10.36
-4.69%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago